{"preliminary_commentary":{"by_channel":{"x_thread":50,"podcast":23,"youtube":22},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05361395\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"DeLLphi-303","nct_id":"NCT05361395","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dellphi-303-nct05361395. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Tarlatamab+Atezolizumab+Carboplatin+Etoposide","label":"Part 1: Dose Exploration Combination Regimen 1","type":"EXPERIMENTAL"},{"description":"Tarlatamab+Atezolizumab+Carboplatin+Etoposide","label":"Part 2: Dose Exploration Combination Regimen 2","type":"EXPERIMENTAL"},{"description":"Tarlatamab+Atezolizumab+Carboplatin+Etoposide","label":"Part 3: Dose Exploration Combination Regimen 3","type":"EXPERIMENTAL"},{"description":"Expansion of Part 1, Part 2, or Part 3 with Atezolizumab","label":"Part 4: Dose Expansion","type":"EXPERIMENTAL"},{"description":"Tarlatamab+Atezolizumab","label":"Part 5: Dose Exploration Maintenance","type":"EXPERIMENTAL"},{"description":"Expansion of Part 5 with Atezolizumab","label":"Part 6: Dose Expansion Maintenance","type":"EXPERIMENTAL"},{"description":"Expansion of Part 1, 2, or 3 with Durvalumab","label":"Part 7: Dose Expansion","type":"EXPERIMENTAL"},{"description":"Expansion of Part 5 with Durvalumab","label":"Part 8: Dose Expansion Maintenance","type":"EXPERIMENTAL"},{"description":"Expansion with Tarlatamab+Durvalumab","label":"Part 9: Dose Expansion Maintenance","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-05-30","type":"ESTIMATED"},"conditions":["Extensive Stage Small Cell Lung Cancer"],"enrollment":{"count":184,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Tarlatamab","otherNames":["AMG 757"],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Etoposide","otherNames":[],"type":"DRUG"},{"name":"Atezolizumab","otherNames":["Tecentriq"],"type":"DRUG"},{"name":"Durvalumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-09","lead_sponsor":"Amgen","official_title":"A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung (DeLLphi-303)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2030-05-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of Participants with a Dose Limiting Toxicity (DLT)","timeFrame":"24 months"},{"measure":"Number of Participants with Treatment-emergent Adverse Events (TEAE)","timeFrame":"24 months"},{"measure":"Number of Participants with Treatment-related Adverse Events","timeFrame":"24 months"},{"measure":"Number of Participants with Clinically Significant Changes in Vital Signs","timeFrame":"24 months"},{"measure":"Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Measurements","timeFrame":"24 months"},{"measure":"Number of Participants with Clinically Significant Changes in Clinical Laboratory Tests","timeFrame":"24 months"}],"references":[{"citation":"Paulson KG, Lau SCM, Ahn MJ, Moskovitz M, Pogorzelski M, Hafliger S, Parkes A, Zhang Y, Hamidi A, Thompson CG, Wermke M. Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study. Lancet Oncol. 2025 Oct;26(10):1300-1311. doi: 10.1016/S1470-2045(25)00480-2. Epub 2025 Sep 8.","pmid":"40934933","type":"BACKGROUND"}],"start_date":{"date":"2022-08-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)","url":"https://clinicaltrials.gov/study/NCT05361395"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dellphi-303-nct05361395"}